61984-08-5

Basic information

• Product Name: 7-chloro-3-(hydroxyamino)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
• CAS NO: 61984-08-5
• Molecular Formula: C₁₅H₁₂ClN₃O₂
• Molecular Weight: 301.7277
• Mol File: 61984-08-5.mol
• Article Data: 2

Chemical Properties

• Density: 1.46g/cm³
• Refractive Index: 1.696
• CAS DataBase Reference: 7-chloro-3-(hydroxyamino)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 7-chloro-3-(hydroxyamino)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one(61984-08-5)
• EPA Substance Registry System: 7-chloro-3-(hydroxyamino)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one(61984-08-5)

Safety Data

• Hazardous Substances Data: 61984-08-5(Hazardous Substances Data)

Upstream product

• 7803-49-8 hydroxylamine 
• 5358-44-1 3,7-dichloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepine-2-one 

Relevant articles and documents

In vivo evaluation of substituted 3-amino-1,4-benzodiazepines as anti-depressant, anxiolytic and anti-nociceptive agents

Oxazepam (CAS 604-75-1) 4 a served as building block in the synthesis of substituted 3-amino-l,4-benzodiazepines, which were subsequently tested in various CNS animal models. The hydroxy group of oxazepam was either activated as a chloride (Method A) or as a phos- phor-oxy derivative (Method B) giving the desired 3-amino-l,4-benzodiapines 6 a- 6r in high yields with primary and secondary amines in a typical nucleophilic substitution reaction. Eighteen 3-substi- tuted 1,4-benzodiazepines were prepared and served as new chemical entities and for lead structure discovery. The mixed cholecystokinin (CCK) antagonist 6 e showed anxiolytic and antidepressant effects from 10μg/kg in mice in the elevated x-maze test and the forced swimming test. The CCK 1 antagonist 6 g has shown antidepressant effects from the same dose, but lacked anxiolytic properties. Both compounds potentiated at a dose of 0.5 mg/kg morphine antinocicep- tion with a maximum possible effect (MPE) about 35 %. By assessing initially the MPE of antinocipection for the 18 newly synthesised benzodiazepines in the tail-flick test, 4 other benzodiazepines were found active. In further in vivo evaluation the cyclohexyl derivative 6 i displayed anxiolytic, antidepressant and antinociceptive properties as single agent at a dose of 5 mg/kg without toxicity. The benzodiazepines 6i and 6p, which initially showed a higher MPE in terms of morphine potentiation (43/44%) showed analgesic effects as single agents, without having anxiolytic or antidepressant properties. The amino-piperidinyl derivative 6 p displayed a similar dose-response relationship to morphine, but was 3 times more potent. ECV Editio Cantor Verlag, Aulendorf (Germany).